Ollin Biosciences Secures $330M to Push Next-Gen Eye Disease Drug Into Phase 3
A potent bispecific antibody showed faster vision gains than a leading rival in a 164-patient trial, now heading to global Phase 3.
Summary
Ollin Biosciences has raised $330 million to fund Phase 3 trials of OLN324, a next-generation antibody targeting two proteins that drive vision loss in diabetic macular edema and wet age-related macular degeneration. In a 164-patient mid-stage trial called JADE, OLN324 outperformed faricimab — currently one of the leading treatments — on anatomic improvements and vision gains. The drug works by blocking both VEGF and Ang2, two signaling molecules that cause abnormal blood vessel growth in the eye. With FDA end-of-phase-2 clearance and European Medicines Agency input secured, global Phase 3 trials are set to begin in the second half of 2026. Age-related macular degeneration is a leading cause of blindness in older adults, making this a directly relevant longevity and healthspan concern.
Detailed Summary
Age-related macular degeneration and diabetic macular edema are two of the most common causes of severe vision loss in older adults, significantly impairing quality of life and independence. Effective treatment options exist but carry limitations, and a next-generation approach that outperforms current therapies could meaningfully preserve healthspan for millions of aging individuals worldwide.
Ollin Biosciences has secured $330 million in a heavily oversubscribed Series B round to advance OLN324 — a bispecific antibody that simultaneously blocks VEGF and Ang2, two proteins responsible for the abnormal leaky blood vessel growth that destroys central vision. By targeting both pathways at once, OLN324 is designed to address disease mechanisms that single-target drugs like ranibizumab or bevacizumab cannot fully suppress.
In the randomized JADE Phase 2 study involving 164 patients, OLN324 demonstrated faster and greater anatomic improvements compared to faricimab, currently considered the most advanced approved bispecific antibody for these indications. Numerically greater vision gains were also observed, though trial size warrants cautious interpretation until Phase 3 data mature.
Ollin has completed an End-of-Phase 2 meeting with the US FDA and received scientific advice from the European Medicines Agency, two critical regulatory milestones that clear the path toward large-scale pivotal trials. Global Phase 3 trials are planned for the second half of 2026, with China and South Korea included through a partnership with Innovent Biologics, the drug's original discoverer.
For health-conscious adults and clinicians focused on aging, preservation of vision is a critical and often underappreciated component of long-term independence and quality of life. If Phase 3 results confirm Phase 2 signals, OLN324 could become a new standard of care for two of the most prevalent age-related eye diseases, offering stronger and potentially longer-lasting vision protection.
Key Findings
- OLN324 showed faster and greater anatomic eye improvements versus faricimab in a 164-patient Phase 2 trial.
- The drug targets both VEGF and Ang2 simultaneously, potentially offering broader disease control than single-target therapies.
- FDA End-of-Phase 2 meeting completed and EMA scientific advice received, clearing the regulatory path to Phase 3.
- Global Phase 3 trials are set to launch in H2 2026, including China and South Korea via Innovent partnership.
- $330M oversubscribed raise signals strong institutional confidence in the drug's commercial and clinical potential.
Methodology
This is a news report summarizing a financing announcement and Phase 2 trial results from Ollin Biosciences. Evidence basis is a 164-patient randomized trial (JADE study); full peer-reviewed data have not been cited. Source is Longevity.Technology, a credible longevity-focused outlet, but this article reflects company-issued claims.
Study Limitations
Phase 2 data from 164 patients may not fully predict Phase 3 outcomes; numerically greater vision gains require statistical confirmation in larger trials. Trial results are reported via company press materials, not yet peer-reviewed publications. Comparative efficacy versus other approved agents beyond faricimab has not been described in this report.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: